Van Qt Truong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Van Qt Truong has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Marylyn DeRiggi Ritchie
Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
3 shared publications - Britney E. Graham
Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
2 shared publications - Jason H. Moore
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, USA
2 shared publications - Joseph D. Romano
University of Pennsylvania
2 shared publications - Li Shen
University of Pennsylvania
2 shared publications - Mythreye Venkatesan
Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
2 shared publications
Latest Publications
- Open Access
TS-Zarr: a cloud-optimized Zarr layout for viewing and analyzing biomedical time series
Background: Biomedical time series are recorded at high sampling rates for hours to days across tens to hundreds of channels. Each recording occupies gigabytes to terabytes of storage. FAIR data sharing requirements often place recordings in cloud storage. Visual analysis requires downsampling windows wider than a few seconds to the pixel width of the screen. Visualization tools therefore either read a local copy of the recording or query a dedicated resampling server in front of the data. Findings: We present TS-Zarr, a Zarr v3 layout for time series data. It stores the samples of each channel alongside a pyramid of summary statistics at progressively coarser levels. Zarr on cloud storage offers low-latency, high-throughput parallel reads. The layout lets a reader fetch only the channels and windows it needs. These targeted reads scale better than the same reads from HDF5 and EDF. Precomputed levels trade additional storage and error-bound signal transformation for faster and more scalable visual analysis that moves from the whole recording to narrow windows. As users grow and windows widen, precomputed reads from cloud storage scale beyond the point at which a resampling server fails. Conclusions: Precomputed levels let researchers visualize a recording without downloading a local copy or querying a dedicated resampling server. The time to read a view remains bounded as the window under view widens. Zarr on cloud storage also provides efficient, highly parallelizable, targeted reads of raw sample data for analysis.
Open AccessTS-Zarr: a cloud-optimized Zarr layout for viewing and analyzing biomedical time series
Background: Biomedical time series are recorded at high sampling rates for hours to days across tens to hundreds of channels. Each recording occupies gigabytes to terabytes of storage. FAIR data sharing requirements often place recordings in cloud storage. Visual analysis requires downsampling windows wider than a few seconds to the pixel width of the screen. Visualization tools therefore either read a local copy of the recording or query a dedicated resampling server in front of the data. Findings: We present TS-Zarr, a Zarr v3 layout for time series data. It stores the samples of each channel alongside a pyramid of summary statistics at progressively coarser levels. Zarr on cloud storage offers low-latency, high-throughput parallel reads. The layout lets a reader fetch only the channels and windows it needs. These targeted reads scale better than the same reads from HDF5 and EDF. Precomputed levels trade additional storage and error-bound signal transformation for faster and more scalable visual analysis that moves from the whole recording to narrow windows. As users grow and windows widen, precomputed reads from cloud storage scale beyond the point at which a resampling server fails. Conclusions: Precomputed levels let researchers visualize a recording without downloading a local copy or querying a dedicated resampling server. The time to read a view remains bounded as the window under view widens. Zarr on cloud storage also provides efficient, highly parallelizable, targeted reads of raw sample data for analysis.
- Open Access
- 3 July 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (4)
Eras of bioinformatics technologies from command-line interfaces to artificial intelligence (AI) chatbots
Over the past 75 years, especially the recent quarter century, bioinformatics has undergone a profound transformation, evolving from a specialized field of command-line tools to a cornerstone of modern biomedical and life sciences. We trace this journey through distinct technological eras driven by exponential biological data growth and parallel computational advances. The genomic revolution established foundational sequence analysis tools and was rapidly followed by the next-generation sequencing era, when unprecedented data volumes shifted the bottleneck from generation to analysis. This drove the development of web servers, cloud platforms, and containerized workflows to address scalability, accessibility, and reproducibility challenges. We now stand in the artificial intelligence (AI)-driven era, where deep learning (e.g. AlphaFold series) and large language models reshape structural biology, multi-modal data integration, and how researchers interact with tools through natural language prompting. This review highlights a recurring pattern as each technological era lowers barriers to entry, it simultaneously introduces new questions about transparency, trust, and rigor. By framing the popular rise of AI within this historical context, we provide a critical roadmap for navigating the cultural, ethical, and technical crossroads facing the next generation of bioinformatics.
- 3 July 2026
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 27 (4)
Open AccessEras of bioinformatics technologies from command-line interfaces to artificial intelligence (AI) chatbots
Over the past 75 years, especially the recent quarter century, bioinformatics has undergone a profound transformation, evolving from a specialized field of command-line tools to a cornerstone of modern biomedical and life sciences. We trace this journey through distinct technological eras driven by exponential biological data growth and parallel computational advances. The genomic revolution established foundational sequence analysis tools and was rapidly followed by the next-generation sequencing era, when unprecedented data volumes shifted the bottleneck from generation to analysis. This drove the development of web servers, cloud platforms, and containerized workflows to address scalability, accessibility, and reproducibility challenges. We now stand in the artificial intelligence (AI)-driven era, where deep learning (e.g. AlphaFold series) and large language models reshape structural biology, multi-modal data integration, and how researchers interact with tools through natural language prompting. This review highlights a recurring pattern as each technological era lowers barriers to entry, it simultaneously introduces new questions about transparency, trust, and rigor. By framing the popular rise of AI within this historical context, we provide a critical roadmap for navigating the cultural, ethical, and technical crossroads facing the next generation of bioinformatics.
- Open Access
- 18 April 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e46777
The Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research
Background: As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. Objective: We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. Methods: We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. Results: AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. Conclusions: AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.
- 18 April 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e46777
Open AccessThe Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research
Background: As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. Objective: We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. Methods: We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. Results: AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. Conclusions: AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.
- Open Access
- 24 February 2023
- Published by JMIR Publications Inc. in JMIR Preprints
The Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research (Preprint)
BACKGROUND As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. OBJECTIVE We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. METHODS We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. RESULTS AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. CONCLUSIONS AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.
- 24 February 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Alzheimer’s Knowledge Base: A Knowledge Graph for Alzheimer Disease Research (Preprint)
BACKGROUND As global populations age and become susceptible to neurodegenerative illnesses, new therapies for Alzheimer disease (AD) are urgently needed. Existing data resources for drug discovery and repurposing fail to capture relationships central to the disease’s etiology and response to drugs. OBJECTIVE We designed the Alzheimer’s Knowledge Base (AlzKB) to alleviate this need by providing a comprehensive knowledge representation of AD etiology and candidate therapeutics. METHODS We designed the AlzKB as a large, heterogeneous graph knowledge base assembled using 22 diverse external data sources describing biological and pharmaceutical entities at different levels of organization (eg, chemicals, genes, anatomy, and diseases). AlzKB uses a Web Ontology Language 2 ontology to enforce semantic consistency and allow for ontological inference. We provide a public version of AlzKB and allow users to run and modify local versions of the knowledge base. RESULTS AlzKB is freely available on the web and currently contains 118,902 entities with 1,309,527 relationships between those entities. To demonstrate its value, we used graph data science and machine learning to (1) propose new therapeutic targets based on similarities of AD to Parkinson disease and (2) repurpose existing drugs that may treat AD. For each use case, AlzKB recovers known therapeutic associations while proposing biologically plausible new ones. CONCLUSIONS AlzKB is a new, publicly available knowledge resource that enables researchers to discover complex translational associations for AD drug discovery. Through 2 use cases, we show that it is a valuable tool for proposing novel therapeutic hypotheses based on public biomedical knowledge.
- Open Access
- 12 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Dissociable neural correlates of uncertainty underlie different exploration strategies
Most real-world decisions involve a delicate balance between exploring unfamiliar alternatives and committing to the best known option. Previous work has shown that humans rely on different forms of uncertainty to negotiate this "explore-exploit” trade-off, yet the neural basis of the underlying computations remains unclear. Using fMRI (n = 31), we find that relative uncertainty is represented in right rostrolateral prefrontal cortex and drives directed exploration, while total uncertainty is represented in right dorsolateral prefrontal cortex and drives random exploration. The decision value signal combining relative and total uncertainty to compute choice is reflected in motor cortex activity. The variance of this signal scales with total uncertainty, consistent with a sampling mechanism for random exploration. Overall, these results are consistent with a hybrid computational architecture in which different uncertainty computations are performed separately and then combined by downstream decision circuits to compute choice.
- 12 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Open AccessDissociable neural correlates of uncertainty underlie different exploration strategies
Most real-world decisions involve a delicate balance between exploring unfamiliar alternatives and committing to the best known option. Previous work has shown that humans rely on different forms of uncertainty to negotiate this "explore-exploit” trade-off, yet the neural basis of the underlying computations remains unclear. Using fMRI (n = 31), we find that relative uncertainty is represented in right rostrolateral prefrontal cortex and drives directed exploration, while total uncertainty is represented in right dorsolateral prefrontal cortex and drives random exploration. The decision value signal combining relative and total uncertainty to compute choice is reflected in motor cortex activity. The variance of this signal scales with total uncertainty, consistent with a sampling mechanism for random exploration. Overall, these results are consistent with a hybrid computational architecture in which different uncertainty computations are performed separately and then combined by downstream decision circuits to compute choice.